Dual-incretin research peptide for metabolic-pathway studies.
- Dose
- 10 mg
- Batch
- 268008
GLP-2 (TRZ)
TRZ (LY3298176) — synthetic 39-residue dual GIP and GLP-1 receptor agonist peptide
For research purposes only — This compound is not FDA approved. All data presented is from clinical trials for educational reference.
Dual-incretin research peptide for metabolic-pathway studies.
Members get 10% off every order, on top of volume pricing — become a member with a free account.
Volume savings are applied automatically at checkout. Larger orders: support@alptide.ch
- Lab
- Janoshik Analytical
- Methods
- HPLC · LC-MS
For laboratory research use only. Not for human consumption.
Technical specifications
- Type
- Peptide
- Scientific name
- TRZ (LY3298176) — synthetic 39-residue dual GIP and GLP-1 receptor agonist peptide
- Amino acids
- 39
- Sequence
- YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPS
- Molecular weight
- 4813.53 g/mol
- Formula
- C225H348N48O68
- CAS
- 2023788-19-2
- Origin
- Engineered from the human GIP sequence: 39 residues with aminoisobutyric acid (Aib, shown as X) at positions 2 and 13, a C-terminal amide, and a C20 diacid–γGlu–(AEEA)2 chain on Lys20; the catalog label "GLP-2" is a vendor designation, not glucagon-like peptide-2.
- Lyophilized (powder)
- -20°C · stable long-term; -80°C for extended archival storage. Protect from light and moisture.
- Reconstituted
- 2-8°C · use within 30 days; avoid repeated freeze-thaw cycles. The FDA-approved solution formulation is likewise stored refrigerated at 2-8°C.
- Room temperature
- Lyophilized powder tolerates brief ambient exposure during shipping and handling, but sustained storage above 25°C accelerates deamidation, oxidation and aggregation. For reference, the approved solution product is labeled for storage at up to 30°C for no more than 21 days, after which it must be discarded — treat ambient exposure of reconstituted material as a stability limit, not a storage condition.
Peer-reviewed research
Published research and registered trials involving this compound. Provided for educational reference only — none of it is a claim about this product.
- Molecular MetabolismLY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of conceptCoskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A2018DOI: 10.1016/j.molmet.2018.09.009PMID: 30473097
- JCI InsightTRZ is an imbalanced and biased dual GIP and GLP-1 receptor agonistWillard FS, Douros JD, Gabe MBN, Showalter AD, Wainscott DB, Suter TM, Capozzi ME, van der Velden WJC, Stutsman C, Cardona GR, Urva S, Emmerson PJ, Holst JJ, D'Alessio DA, Coghlan MP, Rosenkilde MM, Campbell JE, Sloop KW2020DOI: 10.1172/jci.insight.140532PMID: 32730231
- New England Journal of MedicineTRZ versus Semaglutide Once Weekly in Patients with Type 2 DiabetesFrías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators2021DOI: 10.1056/NEJMoa2107519PMID: 34170647
- New England Journal of MedicineTRZ Once Weekly for the Treatment of ObesityJastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators2022DOI: 10.1056/NEJMoa2206038PMID: 35658024
- Cardiovascular DiabetologyTRZ, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reductionNauck MA, D'Alessio DA2022DOI: 10.1186/s12933-022-01604-7PMID: 36050763
- New England Journal of MedicineTRZ for the Treatment of Obstructive Sleep Apnea and ObesityMalhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, Sands SA, Schwab RJ, Dunn JP, Chakladar S, Bunck MC, Bednarik J; SURMOUNT-OSA Investigators2024DOI: 10.1056/NEJMoa2404881PMID: 38912654
More in Metabolic
NAD+
500 mg / vial
Metabolic cofactor supplied for cellular energy and redox-pathway research.
Bacteriostatic Water
3 mL / vial
Laboratory diluent supplied for controlled reconstitution and handling workflows.
5-Amino-1MQ
50 mg / vial
Small-molecule research compound catalogued for metabolic-pathway studies.
AOD-9604
10 mg / vial
Growth-hormone-fragment research peptide catalogued for metabolic-pathway studies.